Justin D. McCallen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Justin D. McCallen has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Tim F. Greten
Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
5 shared publications - Benjamin Ruf
Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
4 shared publications - Chi Ma
Gastrointestinal Malignancy Section, Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
4 shared publications - John C. McVey
Division of Endocrine and Oncology Surgical, Department of Surgery, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA
4 shared publications Laurence P. Diggs
Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
4 shared publications- Bernd Heinrich
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
3 shared publications
Latest Publications
- 9 December 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (9) , 2149-2157
An Eosinophilic Esophagitis Endoscopic Reference Score Threshold of 2 or Less Is Robust for Assessing Endoscopic Response to Treatment of Eosinophilic Esophagitis
INTRODUCTION: Assessment of eosinophilic esophagitis (EoE) endoscopic findings is critical in determining disease activity. However, response thresholds for the EoE Endoscopy Reference Score (EREFS) are not definitively established. We assessed EREFS response thresholds in patients with EoE treated with topical corticosteroids. METHODS: We conducted a retrospective cohort study of newly diagnosed patients with EoE treated with topical corticosteroid who had a follow-up endoscopy with biopsy and EREFS assessed pretreatment/post-treatment. We explored endoscopic response thresholds. Patients with and without endoscopic response were compared and predictors of response were determined. Histologic and global symptom responses were determined and residual endoscopic findings calculated. RESULTS: Of 333 patients, 219 (68%), 206 (62%), 142 (43%), 70 (21%), 139 (42%), and 142 (43%) met response thresholds for EREFS ≤2, EREFS ≤2 with no components >1 nor worsening of any component, EREFS ≤1, EREFS = 0, inflammatory subscore = 0, and fibrostenotic subscore = 0, respectively. On multivariate analysis, lower body mass index (adjusted odds ratio [aOR]: 0.90; 95% confidence interval [CI]: 0.85–0.95), heartburn (aOR: 2.74; 95% CI: 1.37–5.48), and lower total baseline EREFS (aOR: 0.57; 95% CI: 0.29–0.71) independently predicted EREFS ≤2. After treatment, 74% with EREFS≤2 vs 23% with EREFS>2 ( P < 0.001) had histologic response at P < 0.001) and had minimal residual endoscopic findings. Outcomes stratified for adults and children were comparable with the entire cohort. DISCUSSION: Post-treatment EREFS ≤2 was consistent with symptom and histologic response for the entire cohort. These data support EREFS ≤2 as a robust threshold to define endoscopic response.
- 9 December 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (9) , 2149-2157
An Eosinophilic Esophagitis Endoscopic Reference Score Threshold of 2 or Less Is Robust for Assessing Endoscopic Response to Treatment of Eosinophilic Esophagitis
INTRODUCTION: Assessment of eosinophilic esophagitis (EoE) endoscopic findings is critical in determining disease activity. However, response thresholds for the EoE Endoscopy Reference Score (EREFS) are not definitively established. We assessed EREFS response thresholds in patients with EoE treated with topical corticosteroids. METHODS: We conducted a retrospective cohort study of newly diagnosed patients with EoE treated with topical corticosteroid who had a follow-up endoscopy with biopsy and EREFS assessed pretreatment/post-treatment. We explored endoscopic response thresholds. Patients with and without endoscopic response were compared and predictors of response were determined. Histologic and global symptom responses were determined and residual endoscopic findings calculated. RESULTS: Of 333 patients, 219 (68%), 206 (62%), 142 (43%), 70 (21%), 139 (42%), and 142 (43%) met response thresholds for EREFS ≤2, EREFS ≤2 with no components >1 nor worsening of any component, EREFS ≤1, EREFS = 0, inflammatory subscore = 0, and fibrostenotic subscore = 0, respectively. On multivariate analysis, lower body mass index (adjusted odds ratio [aOR]: 0.90; 95% confidence interval [CI]: 0.85–0.95), heartburn (aOR: 2.74; 95% CI: 1.37–5.48), and lower total baseline EREFS (aOR: 0.57; 95% CI: 0.29–0.71) independently predicted EREFS ≤2. After treatment, 74% with EREFS≤2 vs 23% with EREFS>2 ( P < 0.001) had histologic response at P < 0.001) and had minimal residual endoscopic findings. Outcomes stratified for adults and children were comparable with the entire cohort. DISCUSSION: Post-treatment EREFS ≤2 was consistent with symptom and histologic response for the entire cohort. These data support EREFS ≤2 as a robust threshold to define endoscopic response.
- 1 September 2022
- Published by Elsevier in Cancer Cell
- Vol. 40 (9) , 986-998.e5
Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD
- 1 September 2022
- Published by Elsevier in Cancer Cell
- Vol. 40 (9) , 986-998.e5
Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD
- Top Cited Papers
- 1 April 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (3) , 748-760
Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD
- 1 April 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (3) , 748-760
Top Cited PapersMetformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD
- Open Access
NAFLD indirectly impairs antigen-specific CD8+ T cell immunity against liver cancer in mice
- Open Access
- 1 June 2021
- Published by Elsevier in STAR Protocols
- Vol. 2 (2) , 100517
Evaluating the impact of hydroxychloroquine on mouse lymphocyte proliferation and cytokine production in vivo and in vitro
- 1 June 2021
- Published by Elsevier in STAR Protocols
- Vol. 2 (2) , 100517
Open AccessEvaluating the impact of hydroxychloroquine on mouse lymphocyte proliferation and cytokine production in vivo and in vitro
- 1 October 2020
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 13 (10) , 1223-1225
Electrocardiographic Changes and Arrhythmias in Hospitalized Patients With COVID-19
- 1 October 2020
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 13 (10) , 1223-1225
Electrocardiographic Changes and Arrhythmias in Hospitalized Patients With COVID-19
- 1 November 2017
- Published by Elsevier in Acta Biomaterialia
- Vol. 63, 181-189
Multivalent interactions between streptavidin-based pretargeting fusion proteins and cell receptors impede efficient internalization of biotinylated nanoparticles
- 1 November 2017
- Published by Elsevier in Acta Biomaterialia
- Vol. 63, 181-189
Multivalent interactions between streptavidin-based pretargeting fusion proteins and cell receptors impede efficient internalization of biotinylated nanoparticles